All News
Filter News
Found 2,991 articles
-
The RET kinase inhibitor showed “statistically significant and clinically meaningful improvements” in progression-free survival compared to Exelixis’ Cabometyx and Sanofi’s Caprelsa.
-
Seagen Phase 3 Trial of TUKYSA® (tucatinib) in Combination with Antibody-Drug Conjugate ado-trastuzumab emtansine Meets Primary Endpoint of Progression-Free Survival in Patients with Previously Treated HER2-Positive Metastatic Breast Cancer
8/16/2023
Seagen Phase 3 Trial of TUKYSA ® (tucatinib) in Combination with Antibody-Drug Conjugate ado-trastuzumab emtansine Meets Primary Endpoint of Progression-Free Survival in Patients with Previously Treated HER2-Positive Metastatic Breast Cancer.
-
Apex Labs announces the appointment of Chief Medical Officer & Chief Commercial Officer
8/10/2023
Apex Labs Ltd. (APEX or the Company), a pharmaceutical company transforming the standard of mental health care with clinically proven psilocybin treatments, announces the addition of two new executives to the c-suite, psychiatrist Dr. Mark Johnston, MD, FRCPC, as Chief Medical Officer and Greg Rutherford as Chief Commercial Officer.
-
Repare Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results
8/9/2023
Repare Therapeutics Inc., a leading clinical-stage precision oncology company, reported financial results for the second quarter ended June 30, 2023.
-
Alnylam Pharmaceuticals Reports Second Quarter 2023 Financial Results and Highlights Recent Period Activity
8/3/2023
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the second quarter ended June 30, 2023 and reviewed recent business highlights.
-
Lineage Cell Therapeutics to Report Second Quarter 2023 Financial Results and Provide Business Update on August 10, 2023
8/3/2023
Lineage Cell Therapeutics, Inc. today announced that it will report its second quarter 2023 financial and operating results on Thursday, August 10, 2023, following the close of the U.S. financial markets.
-
Seagen Second Quarter 2023 Financial Results Demonstrate Exceptional Commercial Performance Driving Record Product Sales with Strong Growth and Momentum
8/2/2023
Seagen Inc. (Nasdaq:SGEN) (Seagen or the Company) reported financial results today for the second quarter ended June 30, 2023, highlighting record net product sales, with significant year-over-year growth of 26 percent.
-
Nexo Therapeutics Launches With $60 Million Series A Financing
7/26/2023
Nexo Therapeutics today emerged from stealth with a $60 million Series A financing.
-
Embattled SQZ Biotechnologies announced Tuesday that the Swiss biotech will not exercise its option for HPV 16 positive solid tumors under the SQZ-APC-HPV program.
-
ADLM Announces 2023 Top Corporate Supporter Award Recipients and Thanks Them for Invaluable Support
7/25/2023
The Association for Diagnostics & Laboratory Medicine is pleased to announce the recipients of its 2023 Top Corporate Supporter Award, a distinction given to companies and organizations that generously support the association through advertising, sponsorships, and exhibits.
-
The tech giant is investing $50 million in the Utah-based biotech to accelerate development of its AI foundation models for drug discovery.
-
After paying $300 million upfront to BeiGene for option rights to ociperlimab in December 2021, Novartis has dropped the agreement and given the rights back to the Chinese biotech.
-
The company has signed a memorandum of understanding and land collaboration agreement to develop medicines exclusively for Chinese use.
-
Microbial Fermentation Market Size to Surpass USD 54.62 BN by 2032
6/27/2023
The global microbial fermentation technology market size is expected to surpass around USD 54.62 billion by 2032 and is poised to grow at a CAGR of 5.84% from 2023 to 2032.
-
AACC Elects New Leaders to Serve Terms Starting in August 2023
6/27/2023
AACC, a global scientific and medical professional organization dedicated to better health through laboratory medicine, is pleased to announce that Anthony A. Killeen, MB, BCh, PhD, MSc, has been elected to serve on the AACC board of directors as president-elect starting in August 2023.
-
Sun Pharma Announces Health Canada Approval of (PR)ABSORICA LD (isotretinoin capsules) for Treatment of Severe Nodular Acne
6/26/2023
Sun Pharma Canada Inc., a wholly owned subsidiary of Sun Pharmaceutical Industries Limited (Reuters: SUN.BO) (Bloomberg: SUNP IN) (NSE: SUNPHARMA) (BSE: 524715), "Sun Pharma" is pleased to announce Health Canada's approval of PRABSORICA LD® (isotretinoin capsules).
-
Orthofix Announces Changes to Board of Directors - June 20, 2023
6/20/2023
Orthofix Medical Inc., a leading global spine and orthopedics company, announced that Catherine Burzik has been re-appointed as the Chair of the Company’s Board of Directors.
-
FDA Approves Genentech’s Columvi, the First and Only Bispecific Antibody With a Fixed-Duration Treatment for People With Relapsed or Refractory Diffuse Large B-cell Lymphoma
6/16/2023
Genentech, a member of the Roche Group, announced that the U.S. Food and Drug Administration has approved Columvi® for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma not otherwise specified or large B-cell lymphoma arising from follicular lymphoma, after two or more lines of systemic therapy.
-
Future Fields and Jenthera Therapeutics Collaborate to Develop Novel Protein for the Delivery of Cancer Biologics
6/13/2023
Future Fields and Jenthera Therapeutics announced a collaboration focused on the manufacturing of a first-of-its-kind cancer-fighting protein.
-
Development in Alzheimer's disease diagnosis in Canada: New tests help patients and caregivers make timely decisions
6/8/2023
Roche Diagnostics, a division of Hoffmann-La Roche Limited, is proud to announce Health Canada approval for its Cerebrospinal Fluid (CSF) assays* to measure three biomarkers that are hallmarks of Alzheimer's pathology, beta-amyloid and tau proteins, in adults aged 55 and older being evaluated for the disease.